Global Primary Hepatocytes Market Forecast
Primary Hepatocytes Market Insights
A Look Back and a Look Forward - Comparative Analysis
The primary hepatocytes market fueled by the increasing adoption of in vitro liver models for drug discovery and toxicology studies during the period from 2019 to 2023. The rising focus of pharmaceutical industry on Drug Metabolism and Pharmacokinetics (DMPK) studies and regulatory requirements to assess hepatotoxicity spurred demand for primary hepatocytes.
Technological advancements in cryopreservation improved cell viability, enabling broader adoption across global markets. However, the market faced challenges, including high costs, limited donor availability, and issues related to the functional variability of hepatocytes.
The market is expected to grow due to advancements in 3D hepatocyte cultures, liver-on-a-chip technology, and personalized medicine applications. These innovations provide more physiologically relevant models for chronic toxicity studies, regenerative medicine, and precision therapies.
The adoption of hepatocytes in emerging markets like Asia Pacific is projected to rise. Regional market growth is driven by increasing pharmaceutical research and development investments and supportive government initiatives. Such regulatory support for alternative testing methods is estimated to further push market growth.
Key Growth Determinants
The growing preference for in vitro models in drug discovery and development is a key driver for the primary hepatocytes market. Primary hepatocytes play a critical role in evaluating drug metabolism, hepatotoxicity, and enzyme activity, providing highly relevant physiological data.
Regulatory agencies like the FDA and EMA emphasize using in vitro studies to improve early-stage drug screening, reducing reliance on animal testing. The shift toward human-relevant cell models is driven by the need for safe and more effective drug candidates.
In vitro hepatocyte assays allow pharmaceutical companies to identify hepatotoxic compounds early in the development pipeline, saving significant costs and time associated with late-stage failures. As the demand for precise Drug Metabolism and Pharmacokinetics (DMPK) data grows, the use of primary hepatocytes as a gold-standard liver model is expected to increase significantly.
Rising Incidence of Liver Diseases and Hepatotoxicity Concerns
The increasing prevalence of liver diseases, such as hepatitis, non-alcoholic fatty liver disease (NAFLD), and cirrhosis, has heightened the demand for effective in vitro models like primary hepatocytes. Such models enable researchers to study liver pathophysiology, test therapeutic responses, and screen compounds for potential hepatotoxic effects.
Liver-related adverse drug reactions remain a leading cause of drug withdrawal from the market, prompting pharmaceutical companies to prioritize hepatotoxicity studies during early drug development. Primary hepatocytes provide a realistic and predictive model to assess liver toxicity and metabolism, ensuring drugs are both safe and effective.
The demand for hepatocyte-based research solutions is rising with the growing global burden of liver diseases, particularly in regions such as North America, Europe, and Asia Pacific. The said trend, coupled with increasing investments in preclinical studies, is expected to propel the growth of the primary hepatocytes market over the forecast period.
Key Growth Barriers
A major challenge in the primary hepatocytes market is the variability in functionality and limited lifespan of hepatocytes in vitro. Once isolated, hepatocytes are prone to rapid dedifferentiation and loss of liver-specific functions, such as metabolic enzyme activity and transporter expression, making long-term studies difficult.
Freshly isolated hepatocytes tend to exhibit high variability between batches due to donor differences like age, health status, or genetic background, which can result in inconsistent experimental outcomes. Even with cryopreservation techniques, maintaining hepatocyte viability and functionality post-thaw can be challenging. This limited functional lifespan reduces the reliability of primary hepatocytes for long-term studies such as chronic toxicity assessments.
Researchers often need to supplement studies with alternative models or continuous primary cell isolation, increasing time and resource requirements. The functional instability and donor-dependent variability continue to impede the market growth pushing researchers to explore robust alternatives, like immortalized cell lines or advanced 3D liver models.
The high cost associated with isolating, storing, and transporting primary hepatocytes remains a significant restraint for the primary hepatocytes market. Isolating hepatocytes from liver tissue is highly labour-intensive and requires advanced technical expertise, contributing to elevated costs. Primary hepatocytes are typically derived from limited and often scarce human or animal liver sources, making large-scale production and availability inconsistent.
Cryopreserved hepatocytes, while offering advantages in shelf life, still involve costly storage infrastructure like ultra-low temperature freezers and specialized shipping methods. The high costs present significant challenges for smaller laboratories, research institutions, and contract research organizations (CROs) with limited budgets.
Ethical concerns and stringent regulations regarding the use of human liver tissues further limit the availability and procurement of primary hepatocytes, creating supply chain bottlenecks. These factors collectively restrict the widespread adoption of hepatocytes, particularly in emerging economies where funding for advanced research models remains inadequate.
Primary Hepatocytes Market Trends and Opportunities
One of the most significant trends in the primary hepatocytes market is the increasing adoption of 3D hepatocyte cultures and liver-on-a-chip models. Traditional 2D cultures of hepatocytes often fail to replicate the complex microenvironment and cell-cell interactions found in vivo, leading to limited accuracy in predicting drug metabolism and toxicity.
3D culture systems allow hepatocytes to form spheroids or organoid-like structures, better mimicking in vivo architecture and physiological functions of the liver. It has significantly improved the relevance and reliability of in vitro studies for drug development, hepatotoxicity screening, and disease modelling.
The emergence of liver-on-a-chip technology, which integrates primary hepatocytes into microfluidic platforms, has further revolutionized hepatocyte-based research. These systems enable dynamic perfusion of nutrients and drugs, resembling the natural liver microenvironment.
Liver-on-a-chip models allow real-time monitoring of hepatocyte behaviour, providing more accurate data on drug clearance rates, enzyme activity, and long-term toxicity. Pharmaceutical companies and research institutions are increasingly adopting these advanced systems to overcome the limitations of traditional models, and accelerate preclinical research. As 3D hepatocyte culture and microfluidic technologies evolve, they are expected to be critical in personalized medicine and regenerative therapies.
Advanced tools are helping researchers better understand liver-specific diseases, such as NAFLD and hepatitis, and test therapies tailored to individual patients. This trend marks a significant shift toward more predictive and physiologically relevant models, enhancing the overall value proposition of the market.
The growing field of personalized medicine presents a significant opportunity for the primary hepatocytes market. Personalized medicine focuses on tailoring treatments to individual genetic profiles and metabolic characteristics, which requires advanced in vitro models like primary hepatocytes to assess drug efficacy and safety at the individual level.
Primary hepatocytes isolated from diverse donor populations can serve as valuable tools to understand inter-individual differences in drug metabolism, enzyme activity, and susceptibility to hepatotoxicity.
Genotyped hepatocytes can predict drug responses in patients with specific genetic variations in liver enzymes, such as those from the cytochrome P450 family. These insights allow pharmaceutical companies to develop targeted therapies, optimize drug dosages, and minimize adverse effects on patients.
Advances in induced pluripotent stem cells (iPSCs) provide opportunities to generate patient-specific hepatocyte-like cells for disease modelling and therapeutic testing. This approach enables researchers to create highly personalized in vitro models of liver function, expanding the potential applications of hepatocytes in clinical research.
How does Regulatory Scenario Shape the Industry?
The regulatory scenario plays a critical role in shaping the primary hepatocytes market, as authorities increasingly emphasize in vitro models to ensure drug safety and efficacy while reducing reliance on animal testing.
Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued guidelines. These guidelines promote the use of primary hepatocytes for drug metabolism, pharmacokinetics (DMPK), and hepatotoxicity testing during preclinical studies.
The FDA's focus on predictive in vitro tools has accelerated the adoption of primary hepatocyte-based assays, such as enzyme activity, transporter inhibition, and clearance studies, as part of Investigational New Drug (IND) applications. Similarly, EMA guidelines encourage integrating hepatocyte models to evaluate drug-drug interactions and liver enzyme induction/inhibition.
The regulatory push for 3D cell cultures and advanced hepatocyte platforms like liver-on-a-chip has strengthened the market, as these models offer more accurate, reproducible data. Compliance with evolving regulatory frameworks ensures the market growth, making hepatocyte-based assays indispensable for pharmaceutical research and development and safety testing.
Segments Covered in the Report
Cryopreserved suspension hepatocytes are liver cells that have been isolated, rapidly frozen, and stored at ultra-low temperatures to preserve their viability and functionality. This preservation method allows for a readily available supply of hepatocytes, facilitating consistent and reproducible results in various research and industrial applications. This product type in the primary hepatocytes market to account for 40% market share.
Cryopreservation significantly prolongs the usability of hepatocytes, enabling researchers to maintain a consistent supply without the immediate need for fresh tissue samples. The ability to store and quickly thaw hepatocytes ensures they are readily accessible for time-sensitive experiments and studies. Utilizing hepatocytes from the same cryopreserved batch reduces variability in experimental outcomes, enhancing data reliability.
Cell viability assays are essential tools used to assess the health and functionality of hepatocytes by measuring the proportion of live, healthy cells within a population. This segment is estimated to account for a 25% share in primary hepatocytes market. These assays are crucial in various applications, including drug development, toxicity testing, and disease research. They provide insights into the cytotoxic effects of compounds and the overall condition of cell cultures.
Cell viability assays enable researchers to determine the toxic effects of new drug candidates on hepatocytes, ensuring the safety and efficacy of pharmaceutical compounds. By evaluating cell health, these assays assist in refining culture conditions to maintain hepatocyte functionality over extended periods.
Many cell viability assays are adaptable to high-throughput formats, allowing for the rapid screening of numerous compounds and accelerating drug discovery. The growing demand for new therapeutics has led to an upsurge in drug discovery efforts, where cell viability assays play a pivotal role in early-stage screening.
Regional Analysis
North America is the dominant region in the primary hepatocytes market, with the United States playing a pivotal role in this leadership. North America boasts a well-established research ecosystem encompassing numerous biopharmaceutical companies, academic institutions, and contract research organizations.
The robust infrastructure facilitates extensive research and development activities involving primary hepatocytes. A growing focus on developing and utilizing 3D models of hepatocyte culture in the United States further bolsters the regional growth. Such models provide more physiologically relevant data, enhancing the accuracy of drug metabolism and toxicity studies.
The expansion of bio banking initiatives ensures the availability of diverse hepatocyte samples for various research purposes, supporting the region's leading position in the market.
Europe is home to many prominent biotechnology and pharmaceutical companies that invest heavily in drug discovery and preclinical research. Countries such as Germany, the United Kingdom, and France are in charge of cutting-edge research infrastructure and innovation-driven initiatives.
Leading companies increasingly use primary hepatocytes for applications such as drug metabolism, enzyme activity studies, and toxicity screening, which is essential in developing new therapeutic candidates.
European regulatory bodies, such as the European Medicines Agency (EMA), are committed to reducing animal testing while encouraging the use of in vitro models like primary hepatocytes. It aligns with stringent drug safety and efficacy testing regulations, promoting advanced hepatocyte-based assays for toxicity and pharmacokinetic studies.
The EMA's guidance on alternative testing methods has accelerated the adoption of primary hepatocyte cultures for academic research and industrial applications.
Fairfield’s Competitive Landscape Analysis
The presence of several key players, including Thermo Fisher Scientific, Lonza Group, Sekisui XenoTech, and BioIVT, characterizes the primary hepatocytes market. Leading companies dominate the market through robust product portfolios, including cryopreserved and fresh hepatocyte offerings and advanced hepatocyte-based assays for drug metabolism and toxicity studies.
Key players focus on strategic collaborations, product innovations, and expanding biobanking capabilities to strengthen global reach. For example, due to advanced storage technologies, Thermo Fisher and Lonza lead in cryopreserved hepatocytes.
The market also sees increasing competition from contract research organizations (CROs) that provide hepatocyte-based services, catering to pharmaceutical and biotech firms. Partnerships and technological advancements in 3D hepatocyte cultures further intensify the competitive landscape.
Key Market Companies
Recent Industry Developments
An Expert’s Eye
Global Primary Hepatocytes Market is Segmented as-
By Product
By Species
By Assays
By End User
By Region
1. Executive Summary
1.1. Global Primary Hepatocytes Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Production Output and Trade Statistics, 2019 - 2023
3.1. Global Primary Hepatocytes Market Production Output, by Region, Value (US$ Bn) and Volume (Million Units), 2019 - 2023
3.1.1. North America
3.1.2. Europe x`
3.1.3. Asia Pacific
3.1.4. Latin America
3.1.5. Middle East and Africa
4. Price Analysis, 2019 - 2023
4.1. Global Average Price Analysis, by Product/ Species/ Application or Assay/ End User, US$ Per Unit, 2019 - 2023
4.2. Prominent Factor Affecting Primary Hepatocytes Prices
4.3. Global Average Price Analysis, by Region, US$ Per Unit
5. Global Primary Hepatocytes Market Outlook, 2019 - 2031
5.1. Global Primary Hepatocytes Market Outlook, by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
5.1.1. Key Highlights
5.1.1.1. Cryopreserved Suspension Hepatocytes
5.1.1.2. Fresh Suspension Hepatocytes
5.1.1.3. 3D (Spheroid) Hepatocytes
5.1.1.4. Expanded Hepatocytes (Plateable)
5.1.1.5. Non-characterized Hepatocytes
5.2. Global Primary Hepatocytes Market Outlook, by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
5.2.1. Key Highlights
5.2.1.1. Humans
5.2.1.2. Rats
5.2.1.3. Mice
5.2.1.4. Dogs
5.2.1.5. Monkeys
5.2.1.6. Horses
5.2.1.7. Others
5.3. Global Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
5.3.1. Key Highlights
5.3.1.1. Cell Viability Assays
5.3.1.2. Cytochrome Enzyme Activity
5.3.1.3. High Content Cytotoxicity
5.3.1.4. Transporter Inhibition Assays
5.3.1.5. In Vitro Intrinsic Clearance
5.3.1.6. Phospholipoids Assays
5.3.1.7. Others
5.4. Global Primary Hepatocytes Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
5.4.1. Key Highlights
5.4.1.1. Biopharmaceutical Companies
5.4.1.2. Academic and Research Institutes
5.4.1.3. Contract Research Organizations
5.5. Global Primary Hepatocytes Market Outlook, by Region, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
5.5.1. Key Highlights
5.5.1.1. North America
5.5.1.2. Europe
5.5.1.3. Asia Pacific
5.5.1.4. Latin America
5.5.1.5. Middle East & Africa
6. North America Primary Hepatocytes Market Outlook, 2019 - 2031
6.1. North America Primary Hepatocytes Market Outlook, by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.1.1. Key Highlights
6.1.1.1. Cryopreserved Suspension Hepatocytes
6.1.1.2. Fresh Suspension Hepatocytes
6.1.1.3. 3D (Spheroid) Hepatocytes
6.1.1.4. Expanded Hepatocytes (Plateable)
6.1.1.5. Non-characterized Hepatocytes
6.2. North America Primary Hepatocytes Market Outlook, by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.2.1. Key Highlights
6.2.1.1. Humans
6.2.1.2. Rats
6.2.1.3. Mice
6.2.1.4. Dogs
6.2.1.5. Monkeys
6.2.1.6. Horses
6.2.1.7. Others
6.3. North America Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.3.1. Key Highlights
6.3.1.1. Cell Viability Assays
6.3.1.2. Cytochrome Enzyme Activity
6.3.1.3. High Content Cytotoxicity
6.3.1.4. Transporter Inhibition Assays
6.3.1.5. In Vitro Intrinsic Clearance
6.3.1.6. Phospholipoids Assays
6.3.1.7. Others
6.4. North America Primary Hepatocytes Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.4.1. Key Highlights
6.4.1.1. Biopharmaceutical Companies
6.4.1.2. Academic and Research Institutes
6.4.1.3. Contract Research Organizations
6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. North America Primary Hepatocytes Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.5.1. Key Highlights
6.5.1.1. U.S. Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.5.1.2. U.S. Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.5.1.3. U.S. Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.5.1.4. U.S. Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.5.1.5. Canada Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.5.1.6. Canada Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.5.1.7. Canada Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.5.1.8. Canada Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Europe Primary Hepatocytes Market Outlook, 2019 - 2031
7.1. Europe Primary Hepatocytes Market Outlook, by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.1.1. Key Highlights
7.1.1.1. Cryopreserved Suspension Hepatocytes
7.1.1.2. Fresh Suspension Hepatocytes
7.1.1.3. 3D (Spheroid) Hepatocytes
7.1.1.4. Expanded Hepatocytes (Plateable)
7.1.1.5. Non-characterized Hepatocytes
7.2. Europe Primary Hepatocytes Market Outlook, by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.2.1. Key Highlights
7.2.1.1. Humans
7.2.1.2. Rats
7.2.1.3. Mice
7.2.1.4. Dogs
7.2.1.5. Monkeys
7.2.1.6. Horses
7.2.1.7. Others
7.3. Europe Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.3.1. Key Highlights
7.3.1.1. Cell Viability Assays
7.3.1.2. Cytochrome Enzyme Activity
7.3.1.3. High Content Cytotoxicity
7.3.1.4. Transporter Inhibition Assays
7.3.1.5. In Vitro Intrinsic Clearance
7.3.1.6. Phospholipoids Assays
7.3.1.7. Others
7.4. Europe Primary Hepatocytes Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.4.1. Key Highlights
7.4.1.1. Biopharmaceutical Companies
7.4.1.2. Academic and Research Institutes
7.4.1.3. Contract Research Organizations
7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Europe Primary Hepatocytes Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1. Key Highlights
7.5.1.1. Germany Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.2. Germany Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.3. Germany Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.4. Germany Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.5. U.K. Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.6. U.K. Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.7. U.K. Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.8. U.K. Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.9. France Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.10. France Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.11. France Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.12. France Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.13. Italy Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.14. Italy Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.15. Italy Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.16. Italy Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.17. Turkey Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.18. Turkey Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.19. Turkey Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.20. Turkey Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.21. Russia Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.22. Russia Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.23. Russia Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.24. Russia Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.25. Rest of Europe Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.26. Rest of Europe Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.27. Rest of Europe Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.1.28. Rest of Europe Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Asia Pacific Primary Hepatocytes Market Outlook, 2019 - 2031
8.1. Asia Pacific Primary Hepatocytes Market Outlook, by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.1.1. Key Highlights
8.1.1.1. Cryopreserved Suspension Hepatocytes
8.1.1.2. Fresh Suspension Hepatocytes
8.1.1.3. 3D (Spheroid) Hepatocytes
8.1.1.4. Expanded Hepatocytes (Plateable)
8.1.1.5. Non-characterized Hepatocytes
8.2. Asia Pacific Primary Hepatocytes Market Outlook, by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.2.1. Key Highlights
8.2.1.1. Humans
8.2.1.2. Rats
8.2.1.3. Mice
8.2.1.4. Dogs
8.2.1.5. Monkeys
8.2.1.6. Horses
8.2.1.7. Others
8.3. Asia Pacific Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.3.1. Key Highlights
8.3.1.1. Cell Viability Assays
8.3.1.2. Cytochrome Enzyme Activity
8.3.1.3. High Content Cytotoxicity
8.3.1.4. Transporter Inhibition Assays
8.3.1.5. In Vitro Intrinsic Clearance
8.3.1.6. Phospholipoids Assays
8.3.1.7. Others
8.4. Asia Pacific Primary Hepatocytes Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.4.1. Key Highlights
8.4.1.1. Biopharmaceutical Companies
8.4.1.2. Academic and Research Institutes
8.4.1.3. Contract Research Organizations
8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Asia Pacific Primary Hepatocytes Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1. Key Highlights
8.5.1.1. China Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.2. China Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.3. China Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.4. China Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.5. Japan Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.6. Japan Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.7. Japan Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.8. Japan Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.9. South Korea Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.10. South Korea Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.11. South Korea Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.12. South Korea Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.13. India Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.14. India Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.15. India Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.16. India Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.17. Southeast Asia Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.18. Southeast Asia Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.19. Southeast Asia Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.20. Southeast Asia Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.21. Rest of Asia Pacific Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.22. Rest of Asia Pacific Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.23. Rest of Asia Pacific Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.1.24. Rest of Asia Pacific Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Latin America Primary Hepatocytes Market Outlook, 2019 - 2031
9.1. Latin America Primary Hepatocytes Market Outlook, by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.1.1. Key Highlights
9.1.1.1. Cryopreserved Suspension Hepatocytes
9.1.1.2. Fresh Suspension Hepatocytes
9.1.1.3. 3D (Spheroid) Hepatocytes
9.1.1.4. Expanded Hepatocytes (Plateable)
9.1.1.5. Non-characterized Hepatocytes
9.2. Latin America Primary Hepatocytes Market Outlook, by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.2.1. Key Highlights
9.2.1.1. Humans
9.2.1.2. Rats
9.2.1.3. Mice
9.2.1.4. Dogs
9.2.1.5. Monkeys
9.2.1.6. Horses
9.2.1.7. Others
9.3. Latin America Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.3.1. Key Highlights
9.3.1.1. Cell Viability Assays
9.3.1.2. Cytochrome Enzyme Activity
9.3.1.3. High Content Cytotoxicity
9.3.1.4. Transporter Inhibition Assays
9.3.1.5. In Vitro Intrinsic Clearance
9.3.1.6. Phospholipoids Assays
9.3.1.7. Others
9.4. Latin America Primary Hepatocytes Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.4.1. Key Highlights
9.4.1.1. Biopharmaceutical Companies
9.4.1.2. Academic and Research Institutes
9.4.1.3. Contract Research Organizations
9.4.2. BPS Analysis/Market Attractiveness Analysis
9.5. Latin America Primary Hepatocytes Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1. Key Highlights
9.5.1.1. Brazil Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.2. Brazil Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.3. Brazil Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.4. Brazil Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.5. Mexico Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.6. Mexico Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.7. Mexico Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.8. Mexico Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.9. Argentina Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.10. Argentina Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.11. Argentina Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.12. Argentina Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.13. Rest of Latin America Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.14. Rest of Latin America Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.15. Rest of Latin America Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.1.16. Rest of Latin America Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
9.5.2. BPS Analysis/Market Attractiveness Analysis
10. Middle East & Africa Primary Hepatocytes Market Outlook, 2019 - 2031
10.1. Middle East & Africa Primary Hepatocytes Market Outlook, by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.1.1. Key Highlights
10.1.1.1. Cryopreserved Suspension Hepatocytes
10.1.1.2. Fresh Suspension Hepatocytes
10.1.1.3. 3D (Spheroid) Hepatocytes
10.1.1.4. Expanded Hepatocytes (Plateable)
10.1.1.5. Non-characterized Hepatocytes
10.2. Middle East & Africa Primary Hepatocytes Market Outlook, by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.2.1. Key Highlights
10.2.1.1. Humans
10.2.1.2. Rats
10.2.1.3. Mice
10.2.1.4. Dogs
10.2.1.5. Monkeys
10.2.1.6. Horses
10.2.1.7. Others
10.3. Middle East & Africa Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.3.1. Key Highlights
10.3.1.1. Cell Viability Assays
10.3.1.2. Cytochrome Enzyme Activity
10.3.1.3. High Content Cytotoxicity
10.3.1.4. Transporter Inhibition Assays
10.3.1.5. In Vitro Intrinsic Clearance
10.3.1.6. Phospholipoids Assays
10.3.1.7. Others
10.4. Middle East & Africa Primary Hepatocytes Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.4.1. Key Highlights
10.4.1.1. Biopharmaceutical Companies
10.4.1.2. Academic and Research Institutes
10.4.1.3. Contract Research Organizations
10.4.2. BPS Analysis/Market Attractiveness Analysis
10.5. Middle East & Africa Primary Hepatocytes Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1. Key Highlights
10.5.1.1. GCC Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.2. GCC Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.3. GCC Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.4. GCC Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.5. South Africa Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.6. South Africa Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.7. South Africa Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.8. South Africa Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.9. Egypt Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.10. Egypt Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.11. Egypt Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.12. Egypt Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.13. Nigeria Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.14. Nigeria Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.15. Nigeria Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.16. Nigeria Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.17. Rest of Middle East & Africa Primary Hepatocytes Market by Product, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.18. Rest of Middle East & Africa Primary Hepatocytes Market by Species, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.19. Rest of Middle East & Africa Primary Hepatocytes Market by Application or Assay, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.1.20. Rest of Middle East & Africa Primary Hepatocytes Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
10.5.2. BPS Analysis/Market Attractiveness Analysis
11. Competitive Landscape
11.1. Product vs Application or Assay Heatmap
11.2. Company Market Share Analysis, 2023
11.3. Competitive Dashboard
11.4. Company Profiles
11.4.1. Thermo Fisher Scientific
11.4.1.1. Company Overview
11.4.1.2. Product Portfolio
11.4.1.3. Financial Overview
11.4.1.4. Business Strategies and Development
11.4.2. Corning Inc.
11.4.2.1. Company Overview
11.4.2.2. Product Portfolio
11.4.2.3. Financial Overview
11.4.2.4. Business Strategies and Development
11.4.3. Lonza
11.4.3.1. Company Overview
11.4.3.2. Product Portfolio
11.4.3.3. Financial Overview
11.4.3.4. Business Strategies and Development
11.4.4. Axol Bioscience Ltd.
11.4.4.1. Company Overview
11.4.4.2. Product Portfolio
11.4.4.3. Financial Overview
11.4.4.4. Business Strategies and Development
11.4.5. LifeNet Health
11.4.5.1. Company Overview
11.4.5.2. Product Portfolio
11.4.5.3. Financial Overview
11.4.5.4. Business Strategies and Development
11.4.6. SEKISUI XenoTech, LLC
11.4.6.1. Company Overview
11.4.6.2. Product Portfolio
11.4.6.3. Financial Overview
11.4.6.4. Business Strategies and Development
11.4.7. Cytes Biotechnologies
11.4.7.1. Company Overview
11.4.7.2. Product Portfolio
11.4.7.3. Financial Overview
11.4.7.4. Business Strategies and Development
11.4.8. Cell Biologics, Inc.
11.4.8.1. Company Overview
11.4.8.2. Product Portfolio
11.4.8.3. Financial Overview
11.4.8.4. Business Strategies and Development
11.4.9. ZenBio, Inc.
11.4.9.1. Company Overview
11.4.9.2. Product Portfolio
11.4.9.3. Financial Overview
11.4.9.4. Business Strategies and Development
11.4.10. BioIVT.
11.4.10.1. Company Overview
11.4.10.2. Product Portfolio
11.4.10.3. Financial Overview
11.4.10.4. Business Strategies and Development
11.4.11. ScienCell Research Laboratories, Inc.
11.4.11.1. Company Overview
11.4.11.2. Product Portfolio
11.4.11.3. Financial Overview
11.4.11.4. Business Strategies and Development
11.4.12. Kerafast
11.4.12.1. Company Overview
11.4.12.2. Product Portfolio
11.4.12.3. Financial Overview
11.4.12.4. Business Strategies and Development
12. Appendix
12.1. Research Methodology
12.2. Report Assumptions
12.3. Acronyms and Abbreviations
BASE YEAR |
HISTORICAL DATA |
FORECAST PERIOD |
UNITS |
|||
2023 |
|
2019 - 2023 |
2024 - 2031 |
Value: US$ Million |
REPORT FEATURES |
DETAILS |
Product Coverage |
|
Species Coverage |
|
Assays Coverage |
|
End User Coverage |
|
Geographical Coverage |
|
Leading Companies |
|
Report Highlights |
Key Market Indicators, Macro-micro economic impact analysis, Technological Roadmap, Key Trends, Driver, Restraints, and Future Opportunities & Revenue Pockets, Porter’s 5 Forces Analysis, Historical Trend (2019-2021), Market Estimates and Forecast, Market Dynamics, Industry Trends, Competition Landscape, Category, Region, Country-wise Trends & Analysis, COVID-19 Impact Analysis (Demand and Supply Chain) |
Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.
View Methodology